Ivana Kacirova

Dr. Ivana Kacirova

1. Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic
+1
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NPNadežda Petejová
Nadežda Petejová
AMArnost Martinek
Arnost Martinek
JZJosef Zadrazil
Josef Zadrazil
MKMarcela Káňová
Marcela Káňová
VKViktor Klementa
Viktor Klementa
David StejskalDavid Stejskal
David Stejskal
Acute kidney injury is a common complication in critically ill patients with sepsis and/or septic shock. Further, some essential antimicrobial treatment drugs are themselves nephrotoxic. For this reason, timely diagnosis and adequate therapeutic management are paramount. Of potential acute kidney injury (AKI) biomarkers, non-protein-coding RNAs are a subject of ongoing research. This review covers the pathophysiology of vancomycin and gentamicin nephrotoxicity in particular, septic AKI and the microRNAs involved in the pathophysiology of both syndromes. PubMED, UptoDate, MEDLINE and Cochrane databases were searched, using the terms: biomarkers, acute kidney injury, antibiotic nephrotoxicity, sepsis, miRNA and nephrotoxicity. A comprehensive review describing pathophysiology and potential biomarkers of septic and toxic acute kidney injury in septic patients was conducted. In addition, five miRNAs: miR-15a-5p, miR-192-5p, miR-155-5p, miR-486-5p and miR-423-5p specific to septic and toxic acute kidney injury in septic patients, treated by nephrotoxic antibiotic agents (vancomycin and gentamicin) were identified. However, while these are at the stage of clinical testing, preclinical and clinical trials are needed before they can be considered useful biomarkers or therapeutic targets of AKI in the context of antibiotic nephrotoxicity or septic injury.

1 December 2014 in Acta Pharmaceutica
Verified
Journal Article
Open access
PDF file
Milan GrundmannMilan Grundmann
Milan Grundmann
Ivana KacirovaIvana Kacirova
Ivana Kacirova
RURomana Urinovska
Romana Urinovska
Schizophrenia is a severe psychiatric disorder often associated with cognitive impairment and affective, mainly depressive, symptoms. Antipsychotic medication is the primary intervention for stabilization of acute psychotic episodes and prevention of recurrences and relapses in patients with schizophrenia. Typical antipsychotics, the older class of antipsychotic agents, are currently used much less frequently than newer atypical antipsychotics. Therapeutic drug monitoring (TDM) of antipsychotic drugs is the specific method of clinical pharmacology, which involves measurement of drug serum concentrations followed by interpretation and good cooperation with the clinician. TDM is a powerful tool that allows tailor-made treatment for the specific needs of individual patients. It can help in monitoring adherence, dose adjustment, minimizing the risk of toxicity and in cost-effectiveness in the treatment of psychiatric disorders. The review provides complex knowledge indispensable to clinical pharmacologists, pharmacists and clinicians for interpretation of TDM results.

1 October 2012 in Journal of Chromatography B
Verified
Journal Article
Closed access
RURomana Uřinovská
Romana Uřinovská
HBHana Brozmanová
Hana Brozmanová
PŠPavel Šištík
Pavel Šištík
PŠPetr Šilhán
Petr Šilhán
Ivana KacirovaIvana Kacirova
Ivana Kacirova
MGMilan Grundmann
Milan Grundmann


12 December 2012 in Biomedical Papers
Verified
Journal Article
Open access
PDF file
NPNadežda Petejová
Nadežda Petejová
AMArnost Martinek
Arnost Martinek
JZJana Zahalkova
Jana Zahalkova
JĎJana Ďuricová
Jana Ďuricová
HBHana Brozmanova
Hana Brozmanova
Ivana KacirovaIvana Kacirova
Ivana Kacirova
Aims: To determine the extent of vancomycin removal and vancomycin pharmacokinetics in septic patients with AKI using daily hemodialysis with polysulphone high-flux and low-flux membrane. Methods: Five patients received 6 h daily dialysis with...

14 June 2017 in Biomedical Papers
Verified
Journal Article
Open access
PDF file
EVErika Hrudikova Vyskocilova
Erika Hrudikova Vyskocilova
MGMilan Grundmann
Milan Grundmann
JĎJana Ďuricová
Jana Ďuricová
Ivana KacirovaIvana Kacirova
Ivana Kacirova
Amiodarone is the most effective agent in the therapy of arrhythmias. However, the clinical effect of acute and chronic treatment is unclear and there are differences irrespective of comparable plasma/myocardial amiodarone and its metabolite desethylamiodarone concentations as well. Its unusual pharmacokinetics results in interindividual variation in plasma levels. The association between amiodarone and desethylamiodarone plasma levels and clinical efficacy is difficult to evaluate. This review was carried out to assess whether there is any objective correlation between amiodarone and desethylamiodarone plasma levels and the clinical effect. We summarized the results of relevant studies and clarified the relationship between plasma levels and effect vis á vis the pharmacokinetics and pharmacogenetics of this drug. Certain correlation was seen with oral amiodarone therapy, in others, plasma amiodarone levels were unrelated to therapeutic response and showed no correlation with changes in electrocardiogram or electrophysiological parametres. Several studies show that plasma concentration ranging between 0.5 and 2.5 mg/L appears to be the most effective, others demonstrate no difference between responders and non-responders. One way of interpreting plasma levels is to establish an individual patient´s effective concentration. Therapeutic drug monitoring can contribute to determining optimal concentration.